TOKYO, March 9, 2025 /PRNewswire/ — Seven & i Holdings Co., Ltd. (“7&i,” “the Group,” or “the Company”) today sent the following letter to its shareholders to provide additional information related to the Special Committee’s ongoing engagement with Alimentation Couche-Tard (“ACT”) and…

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] The…

NEW YORK, March 9, 2025 /PRNewswire/ — Attorney Advertising– Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AppLovin Corporation (“AppLovin” or “the Company”) (NASDAQ: APP) and certain of its…

NEW YORK, March 9, 2025 /PRNewswire/ — Attorney Advertising– Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQ: MRVI) and…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.